Haisco Pharmaceutical Group (002653) investor relations material

Executive summary

• Achieved revenue of ¥3.10 billion in H1 2026, up 54.71% year-over-year, driven by new overseas licensing and robust product sales.

• Net profit attributable to shareholders reached ¥851 million, a 426.98% increase year-over-year.

• Five innovative drugs now commercialized, with significant international expansion and multiple global licensing deals signed.

• R&D pipeline includes 21 clinical-stage innovative drugs and over 50 early-stage projects across anesthesia, respiratory, autoimmune, oncology, and metabolic diseases.

Financial highlights

• Operating income: ¥3.10 billion, up 54.71% year-over-year.

• Net profit attributable to shareholders: ¥851 million, up 426.98% year-over-year.

• Net profit excluding non-recurring items: ¥752 million, up 324.18% year-over-year.

• Operating cash flow: ¥761 million, up 117.55% year-over-year.

• Gross margin for self-produced products: 82.47%.

Outlook and guidance

• H2 2026 will focus on deepening commercialization of five core innovative drugs and expanding market coverage.

• Continued investment in R&D, especially in biologics and advanced technology platforms.

• Multiple clinical milestones expected in H2, including key readouts for pain, dermatology, and metabolic indications.

• Ongoing international licensing and strategic collaborations to drive long-term growth.